InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China

Marginal zone lymphoma (MZL) is an indolent B-cell non-Hodgkin's lymphoma (NHL). It is the second most prevalent lymphoma in China, accounting for 8.3% of all lymphomas. It mainly affects the ...
PharmaTimes

MINT study results strengthen real‑world evidence for mogamulizumab

Kyowa Kirin International has announced final results from the German MINT study evaluating mogamulizumab in patients with MF ...
Delco Times

HEADstrong Foundation gala, Norwood Social coming up

One Night of the Bee Gees at Lansdowne Theater, Community Arts Center announces Fall Fest lineup, nominate a teacher for ...

Lost and found: Memorial bench recovered for Tipton father after weeks after searching

Joe Hunter didn’t give up hope his daughter’s memorial bench would be found after it swept away in the flood. Tuesday, it was ...
DairyBusiness

Wisner Baum Lawsuit Alleges Syngenta Failed to Warn of Atrazine’s Cancer Risks

Apostolos Panayiotou alleges that nearly three decades of mixing and spraying atrazine-based herbicides in Los ...
agnavigator

Syngenta sued over alleged link between atrazine herbicides & cancer

The lawsuit alleges that Panayiotou developed cancer after routinely mixing, loading, and spraying atrazine products over ...
oncodaily

David Sermer: Excited to Join Legend Biotech as Executive Director

Excited to Join Legend Biotech as Executive Director / cancer, David Sermer, Legend Biotech, OncoDaily, Oncology ...